{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:24:46Z","timestamp":1780593886055,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ijcard.2014.12.055","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:50:53Z","timestamp":1419295853000},"page":"376-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Ranolazine: Drug overview and possible role in primary microvascular angina management"],"prefix":"10.1016","volume":"181","author":[{"given":"Mattia","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Pia","family":"Porretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Gallino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.12.055_bb0005","first-page":"e28","article-title":"Heart disease and stroke statistics\u20142014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0010","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1067\/mhj.2001.114198","article-title":"Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study","volume":"141","author":"Reis","year":"2001","journal-title":"Am. Heart J."},{"issue":"2 Suppl.","key":"10.1016\/j.ijcard.2014.12.055_bb0015","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.cjca.2011.09.006","article-title":"Women, cardiac syndrome X, and microvascular heart disease","volume":"28","author":"Arthur","year":"2012","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0020","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.109.900191","article-title":"Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management","volume":"121","author":"Lanza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40256-013-0052-1","article-title":"Management of microvascular angina pectoris","volume":"14","author":"Lanza","year":"2014","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0030","author":"European Medicines Agency"},{"issue":"Pt 2","key":"10.1016\/j.ijcard.2014.12.055_bb0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1113\/jphysiol.1996.sp021772","article-title":"Hypoxia increases persistent sodium current in rat ventricular myocytes","volume":"497","author":"Ju","year":"1996","journal-title":"J. Physiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0040","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1006\/jmcc.1998.0706","article-title":"Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new method for the measurement of oxygen consumption in muscle strip preparations","volume":"30","author":"Meyer","year":"1998","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0050","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.yjmcc.2006.08.012","article-title":"Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts","volume":"41","author":"Fraser","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0055","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jcmg.2009.09.006","article-title":"A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images","volume":"2","author":"Venkataraman","year":"2009","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00877121","article-title":"Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease","volume":"8","author":"Hayashida","year":"1994","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0065","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1113\/jphysiol.2013.257246","article-title":"Ranolazine recruits muscle microvasculature and enhances insulin action in rats","volume":"591","author":"Fu","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0070","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.phrs.2011.06.018","article-title":"Anolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts","volume":"64","author":"Aldakkak","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.atherosclerosis.2012.10.051","article-title":"Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus","volume":"226","author":"Lamendola","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MCA.0b013e32832a198b","article-title":"Ranolazine improves endothelial function in patients with stable coronary artery disease","volume":"20","author":"Deshmukh","year":"2009","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0110","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0115","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jacc.2006.10.067","article-title":"Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE)","volume":"9","author":"Koren","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0120","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0125","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0130","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","article-title":"Role of ranolazine in angina, heart failure, arrhythmias, and diabetes","volume":"133","author":"Sossalla","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/0091270004273992","article-title":"Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects","volume":"45","author":"Jerling","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0145","author":"Food and Drug Administration"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","article-title":"Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris","volume":"95","author":"Rousseau","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"14s1","key":"10.1016\/j.ijcard.2014.12.055_bb0155","doi-asserted-by":"crossref","first-page":"E1050","DOI":"10.1016\/S0735-1097(11)61050-4","article-title":"Ranolazine refractory angina registry trial: 1-year results","volume":"57","author":"Bennett","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0160","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"Camici","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0165","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0735-1097(94)00507-M","article-title":"Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study","volume":"25","author":"Kaski","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijcard.2008.11.026","article-title":"Long-term prognosis of patients with cardiac syndrome X","volume":"140","author":"Lamendola","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0175","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.CIR.85.3.883","article-title":"Pathophysiological dilemma of syndrome X","volume":"85","author":"Cannon","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0735-1097(10)80122-6","article-title":"Mechanisms of angina pectoris in syndrome X","volume":"17","author":"Maseri","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0140-6736(93)91344-L","article-title":"Insulin resistance in microvascular angina (syndrome X)","volume":"342","author":"Botker","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjcard.2006.07.052","article-title":"Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials","volume":"99","author":"Wenger","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0195","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","article-title":"Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease","volume":"4","author":"Mehta","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","article-title":"Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease","volume":"25","author":"Spertus","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0205","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0002-9149(89)90496-7","article-title":"A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index)","volume":"64","author":"Hlatky","year":"1989","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of ivabradine and ranolazine in patients with microvascular angina pectoris","volume":"112","author":"Villano","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2014.12.055_bb0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.ijcard.2014.12.055_bb0220","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/echo.12674","article-title":"Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease","volume":"32","author":"Tagliamonte","year":"2015","journal-title":"Echocardiography"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314024772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314024772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T19:24:59Z","timestamp":1583868299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314024772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":44,"alternative-id":["S0167527314024772"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.12.055","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ranolazine: Drug overview and possible role in primary microvascular angina management","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.12.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}